Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes

go back to reference Fozza C, Longinotti M (2012) Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes? Eur J Haematol 88(5):380–387CrossRefPubMed Fozza C, Longinotti M (2012) Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes? Eur J Haematol 88(5):380–387CrossRefPubMed

go back to reference Fozza C, Longu F, Contini S, Galleu A, Virdis P, Bonfigli S, Murineddu M, Gabbas A, Longinotti M (2012) Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127(low) regulatory T cells. Acta Haematol 128(3):178–182CrossRefPubMed Fozza C, Longu F, Contini S, Galleu A, Virdis P, Bonfigli S, Murineddu M, Gabbas A, Longinotti M (2012) Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127(low) regulatory T cells. Acta Haematol 128(3):178–182CrossRefPubMed

go back to reference Fozza C (2018) The burden of autoimmunity in myelodysplastic syndromes. Hematol Oncol 36:15–23CrossRefPubMed Fozza C (2018) The burden of autoimmunity in myelodysplastic syndromes. Hematol Oncol 36:15–23CrossRefPubMed

go back to reference Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellví J, Saumell S, Bobillo S, Bosch F, Valcárcel D (2018) Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol 97(8):1349–1356CrossRefPubMed Montoro J, Gallur L, Merchán B, Molero A, Roldán E, Martínez-Valle F, Villacampa G, Navarrete M, Ortega M, Castellví J, Saumell S, Bobillo S, Bosch F, Valcárcel D (2018) Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Ann Hematol 97(8):1349–1356CrossRefPubMed

go back to reference Okamoto T, Okada M, Mori A et al (1997) Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 66(3):345–351CrossRefPubMed Okamoto T, Okada M, Mori A et al (1997) Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 66(3):345–351CrossRefPubMed

go back to reference Zhao S, Mao H, Wang H, Yu J (2002) The relationship between myelodysplastic syndromes and autoimmune disorders. Zhonghua Xue Ye Xue Za Zhi 23(6):311–313PubMed Zhao S, Mao H, Wang H, Yu J (2002) The relationship between myelodysplastic syndromes and autoimmune disorders. Zhonghua Xue Ye Xue Za Zhi 23(6):311–313PubMed

go back to reference de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Lévesque H, Hamidou M, Subra JF, Ifrah N, Belizna C (2011) Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res 63(8):1188–1194CrossRef de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Lévesque H, Hamidou M, Subra JF, Ifrah N, Belizna C (2011) Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res 63(8):1188–1194CrossRef

go back to reference Lee SJ, Park JK, Lee EY, Joo SH, Jung KC, Lee EB, Song YW, Yoon SS (2016) Certain autoimmune manifestations are associated with distinctive karyotypes and outcomes in patients with myelodysplastic syndrome: a retrospective cohort study. Medicine (Baltimore) 95(13):e3091CrossRef Lee SJ, Park JK, Lee EY, Joo SH, Jung KC, Lee EB, Song YW, Yoon SS (2016) Certain autoimmune manifestations are associated with distinctive karyotypes and outcomes in patients with myelodysplastic syndrome: a retrospective cohort study. Medicine (Baltimore) 95(13):e3091CrossRef

go back to reference Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM (2004) Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 43(5):626–632CrossRef Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM (2004) Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 43(5):626–632CrossRef

go back to reference Marisavljević D, Kraguljac N, Rolović Z (2006) Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 23(3):385–391CrossRefPubMed Marisavljević D, Kraguljac N, Rolović Z (2006) Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 23(3):385–391CrossRefPubMed

go back to reference Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, de Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O (2016) Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 55(2):291–300CrossRef Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, de Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O (2016) Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford) 55(2):291–300CrossRef

go back to reference Komrokji RS, Kulasekararaj A, Al Ali NH et al (2016) Autoimmune diseases and myelodysplastic syndromes. Am J Hematol 91(5):E280–E283CrossRefPubMed Komrokji RS, Kulasekararaj A, Al Ali NH et al (2016) Autoimmune diseases and myelodysplastic syndromes. Am J Hematol 91(5):E280–E283CrossRefPubMed

go back to reference Fozza C, Crobu V, Isoni MA, Dore F (2016) The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol 107:90–99CrossRefPubMed Fozza C, Crobu V, Isoni MA, Dore F (2016) The immune landscape of myelodysplastic syndromes. Crit Rev Oncol Hematol 107:90–99CrossRefPubMed

go back to reference Fozza C, Corda G, Barraqueddu F, Virdis P, Contini S, Galleu A, Isoni A, Dore F, Angelucci E, Longinotti M (2015) Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Leuk Res 39(9):957–963CrossRefPubMed Fozza C, Corda G, Barraqueddu F, Virdis P, Contini S, Galleu A, Isoni A, Dore F, Angelucci E, Longinotti M (2015) Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Leuk Res 39(9):957–963CrossRefPubMed